The most popular biologicals currently in use to treat RA are neutralizing antibodies against proinflammatory cytokines, including tumor necrosis factor inhibitors (such as adalimumab, infliximab, and etanercept), anti-CD20 neutralizing antibodies (rituximab), T-cell co-stimulation inhibitors (abatacept), and IL-6R blockers (tocilizumab) [35,36,37]. The gene discussed is TNF; the disease is rheumatoid arthritis.